2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6344 Evaluating the non-infectious therapeutic effects of sars-cov-2 mRNA vaccination in patients with myeloproliferative neoplasms

Esteban Toro Velez, MD, Carolina Velez-Mejia, MD2, Ruchi Desai, MD3
1 Virginia Commonwealth University, Richmond, Virginia, United States
2 Virginia Commonwealth University, Richmond, Virginia, United States
3 Virginia Commonwealth University, Richmond, Virginia, United States

Background:

The SARS-CoV-2 mRNA vaccines gained visibility for cancer care after it was shown that they were immune sensitizers in solid tumors. It was showed that the mRNA vaccines reprogram the tumor microenvironment which can potentiate the effect of established treatment. However, this effect has not been validated in myeloproliferative neoplasms (MPNs). MPNs are clonal hematopoietic stem cell disorders characterized by driver mutations that perpetuate chronic inflammatory signaling and myeloid proliferation. This is the first known assessment of the effect of SARS-CoV-2 mRNA vaccines in patients undergoing treatment for MPNs.

 

Methods:

A retrospective cohort study using the TriNetX Global Collaborative Network was carried out. We included patients ≥ 18 years diagnosed with MPNs between January 2020 and June 2026 who received systemic therapy including hydroxyurea, interferon alpha 2a/2b, luspatercept, lenalidomide, pacritinib, fedratinib, memelotinib or ruxolitinib. Eligible patients had no history of active COVID-19 infection within 6 months of starting treatment and were divided in two groups depending on if they receive or not a SARS-CoV-2 mRNA vaccine within 100 days of treatment initiation. The only variable different among comparison groups was the presence or absence of the vaccine. Cohorts were balanced using propensity score matching for age at diagnosis, female, Black race, Hispanics, hemoglobin, platelet count, comorbidities, and concomitant medications. Kaplan-Meier survival curves were used to assess overall survival (OS) over a 5 year follow up period.

 

Results:  

Among patients with MPNs, 3,079 were vaccinated and 28,392 were unvaccinated. After balancing there were 3,079 patients in each cohort.

 

Patients who received vaccination had better overall survival [p-value of 0.0001] with a survival probability of 80.164% vs 77.562% of those vaccinated vs unvaccinated, respectively. Interestingly there was no statistical difference in the rate of hospitalization (HR 1.041 CI 0.892,1.243), opportunistic infections (HR 0.879, CI 0.612,1.262), thrombosis (HR 0.805 CI 0.637,1.016) or bleeding (HR 0.958 CI 0.795,1.155). When analyzing the prescription for anticoagulation or aspirin it was noted that it was higher for those with vaccines 26.7% vs 17.808% (HR 1.01 CI 0.874,1.167) and 24.544% vs 15.697% (HR 1.042 CI 0.889,1.22), respectively.

 

When doing subgroup analysis, it was noted that the survival benefit persisted for those with polycythemia vera that received vaccination compared to those unvaccinated (p<0.0037, survival probability of 79.929% vs 77.822%, respectively) and those with myelofibrosis (p<0.0192, survival probability of 78.172% vs 73.817%, respectively). However, for patients with essential thrombocytosis there was no difference in overall survival.

 

Conclusions:

Repurposing mRNA vaccines and timing it as part of the cancer treatment for patients with MPNs may improve overall survival for these patients. Physiologically, this survival benefit is likely due vaccine-mediated reprogramming of sensitivity to previously unreactive tumor microenvironments and potentially affecting immunomodulation in the bone marrow. A limitation of our finding is that TriNetX relies on coding accuracy, therefore, prospectively investigating this therapeutic implication is essential to further understand the anti-inflammatory and hematopoietic effect of the mRNA vaccines. However, at this time, SARS-CoV-2 mRNA vaccines seem to be an effective and accessible adjuvant strategy to enhance treatment in patients diagnosed with MPNs. 

Esteban Toro Velez, MD: No relevant conflicts of interest to declare.